Suppression of Prostate Cancer Cell Rolling and Adhesion to Endothelium by 1α,25-Dihydroxyvitamin D3

Department of Urology and Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
American Journal Of Pathology (Impact Factor: 4.6). 02/2011; 178(2):872-80. DOI: 10.1016/j.ajpath.2010.10.036
Source: PubMed

ABSTRACT Adhesion of circulating prostate cancer (PCa) cells to the microvascular endothelium is a critical step during cancer metastasis. To study PCa cell rolling and adhesion behavior, we developed a dynamic flow-based microtube system to mimic the microvascular environment. We found that PCa cell rolling capacity is mediated by E-selectin and can be enhanced by stromal cell-derived factor-1 under different wall shear stresses. Using this device, we tested if the chemopreventive agent, vitamin D, could interfere with PCa cell adhesion. We found that 1α,25-dihydroxyvitamin D(3) (1,25-VD), the bioactive form of vitamin D, reduced PCa cell rolling numbers and increased rolling velocities resulting in a significant decreased number of PCa cells adhering to the microtube. The inhibitory effects of 1,25-VD on PCa cell heterotypic adhesion were further confirmed using microvascular endothelial cells in a static condition. Furthermore, we demonstrated that 1,25-VD can increase E-cadherin expression in PCa cells and promote the homotypic cell-cell aggregation, which can then hinder PCa cell adhesion to the endothelium. Blocking E-cadherin with a neutralizing antibody can reverse 1,25-VD-mediated suppression of PCa cell adhesion to the endothelium. Taken together, our data revealed that 1,25-VD promoted PCa cell aggregation by increasing E-cadherin expression, thus interfering with circulating PCa cell adhesion to microvascular endothelial cells and potentially reducing their metastatic potential.

Download full-text


Available from: Michael R King, Jul 02, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:The interaction between human prostate cancer (PCa) cells and bone marrow (BM) endothelium follows a rolling-and-adhesion cascade mediated by E-selectin ligand (ESL): E-selectin. This adhesion is enabled by elevated expression of α-1,3-fucosyltransferases (FTs), enzymes responsible for ESL-mediated bone metastasis in humans. In contrast, the incidence of bone metastasis in mice is rare.Methods:FT 3, 6 and 7 were overexpressed in mouse PCa cells. The rolling cell number, cell-rolling velocity and transendothelial migration were characterised in vitro. Fucosyltransferases-transduced mouse PCa cells expressing luciferase were inoculated into mice via left ventricle to compare the capability of bone metastasis. Mass spectrometry and immunoprecipitation were utilised for identification of ESLs.Results:Overexpression of FT3, FT6 or FT7 restored ESLs and enabled mouse PCa cells to roll and adhere in E-selectin-functionalised microtubes, similar to trafficking of circulating PCa cells in BM vessels. Following intracardiac inoculation, FT6-transduced cells induced robust bone metastasis in mice. Inhibition of FT6 by a fucose mimetic significantly reduced bone metastasis. Importantly, comparison of FT3, FT6 and FT7 gene expression in existing clinical samples showed significant upregulation of FT6 in PCa-distant metastases.Conclusion:FT6 is a key mediator of PCa cells trafficking to the BM. It may serve as a viable drug target in preclinical tests of therapeutics for reduction of PCa bone metastasis.British Journal of Cancer advance online publication, 31 October 2013; doi:10.1038/bjc.2013.690
    British Journal of Cancer 10/2013; 109(12). DOI:10.1038/bjc.2013.690 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A stable modulation and demodulation technique of the physical address is essential to a HD-DVD system where the physical address is recorded in the form of a modulated wobble. Many modulation techniques have been introduced and adapted for HD-DVD experiments. Among them, the MSK (minimum shift keying) modulation is attracting more attention recently because it has many advantages for the HD-DVD system, such as continuous phase form, constant amplitude envelope, and so on. But the typical coherent MSK demodulator is composed of analog signal multipliers, integrators, and other complicated logic circuit blocks. Therefore, the hardware implementation of the demodulator is very complex and demodulation performance is quite dependent on individual devices. To solve these problems, we propose a new digital non-coherent MSK demodulation technique in this paper.
    Optical Memory and Optical Data Storage Topical Meeting, 2002. International Symposium on; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The complex dynamics of the tumor microenvironment and prostate cancer heterogeneity have confounded efforts to establish suitable preclinical mouse models to represent human cancer progression from early proliferative phenotypes to aggressive, androgen-independent, and invasive metastatic tumors. Current models have been successful in capitulating individual characteristics of the aggressive tumors. However, none of these models comprehensively mimics human cancer progression, establishing the challenge in their exploitation to study human disease. The ability to tailor phenotypic outcomes in mice by compounding mutations to target specific molecular pathways provides a powerful tool toward disruption of signaling pathways contributing to the initiation and progression of castration-resistant prostate cancer. Each model is characterized by unique features contributing to the understanding of prostate tumorigenesis, as well as limitations challenging our knowledge of the mechanisms of cancer development and progression. Emerging strategies utilize genomic manipulation technology to circumvent these limitations toward the formulation of attractive, physiologically relevant models of prostate cancer progression to advanced disease. This review discusses the current value of the widely used and well-characterized mouse models of prostate cancer progression to metastasis, as well as the opportunities begging exploitation for the development of new models for testing the antitumor efficacy of therapeutic strategies and identifying new biomarkers of disease progression.
    Journal of Andrology 06/2011; 33(2):133-44. DOI:10.2164/jandrol.111.013987 · 1.69 Impact Factor